Rosetta gets Notice of Allowance on prostate cancer diagnostic

Rosetta Genomics (ROSG +8.7%) receives a Notice of Allowance from the USPTO for its patent application entitled "Compositions and Methods for Prognosis and Treatment of Prostate Cancer." The patent (No. 13/390,995) claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer.

From other sites
Comments (1)
  • wallace2000
    , contributor
    Comments (56) | Send Message
    This is going to be a stock that explodes and everyone looking back will say, it was so obvious why didn't I see it?


    Their Cancer of Unknown Primary (origin) Test looks at the genomic level to determine where a metasticized cancer came from. It cost $3,500. The average cost to find a CUP origin (biopsies, MRI's, blood tests, etc...) now is about $18,000. There are 200,000 of these cases every year in the U.S.


    If ROSG get 15% of this market with their better mouse trap (cost-down healthcare solution) that will be $105M a year in revenue just for this one test.


    Back of the envelope calculation is that if the $105M hits, that will translate to about $5.70 EPS at current burn rate with 60% product margins. Times a growth multiple of 25, --->$142.50 a share.
    26 Jun 2014, 12:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs